US20040224892A1 - Oligosaccharides in cosmetic or dermatological compositions for stimulating adhesion of keratinocytes to major proteins of the dermoepidermal junction and restoration of epidermal cohesion - Google Patents
Oligosaccharides in cosmetic or dermatological compositions for stimulating adhesion of keratinocytes to major proteins of the dermoepidermal junction and restoration of epidermal cohesion Download PDFInfo
- Publication number
- US20040224892A1 US20040224892A1 US10/839,420 US83942004A US2004224892A1 US 20040224892 A1 US20040224892 A1 US 20040224892A1 US 83942004 A US83942004 A US 83942004A US 2004224892 A1 US2004224892 A1 US 2004224892A1
- Authority
- US
- United States
- Prior art keywords
- composition according
- epidermis
- oligogalacturonides
- hydrolysis
- laminin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- 210000002510 keratinocyte Anatomy 0.000 title claims abstract description 32
- 230000004936 stimulating effect Effects 0.000 title claims abstract description 9
- 239000002537 cosmetic Substances 0.000 title description 12
- 102000004169 proteins and genes Human genes 0.000 title description 11
- 108090000623 proteins and genes Proteins 0.000 title description 11
- 229920001542 oligosaccharide Polymers 0.000 title description 4
- 150000002482 oligosaccharides Chemical class 0.000 title description 4
- 210000002615 epidermis Anatomy 0.000 claims abstract description 33
- 102000008186 Collagen Human genes 0.000 claims abstract description 28
- 108010035532 Collagen Proteins 0.000 claims abstract description 28
- 229920001436 collagen Polymers 0.000 claims abstract description 28
- 238000004891 communication Methods 0.000 claims abstract description 16
- 210000004207 dermis Anatomy 0.000 claims abstract description 15
- 239000001814 pectin Substances 0.000 claims description 27
- 229920001277 pectin Polymers 0.000 claims description 27
- 235000010987 pectin Nutrition 0.000 claims description 27
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 108010059820 Polygalacturonase Proteins 0.000 claims description 20
- 238000006460 hydrolysis reaction Methods 0.000 claims description 17
- 210000003491 skin Anatomy 0.000 claims description 17
- 230000007062 hydrolysis Effects 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 230000032683 aging Effects 0.000 claims description 9
- 108010093305 exopolygalacturonase Proteins 0.000 claims description 8
- 229920006158 high molecular weight polymer Polymers 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- 239000000419 plant extract Substances 0.000 claims description 5
- 238000006116 polymerization reaction Methods 0.000 claims description 5
- 108090000371 Esterases Proteins 0.000 claims description 4
- 102000004317 Lyases Human genes 0.000 claims description 4
- 108090000856 Lyases Proteins 0.000 claims description 4
- 230000007071 enzymatic hydrolysis Effects 0.000 claims description 4
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 3
- 235000013734 beta-carotene Nutrition 0.000 claims description 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 3
- 239000011648 beta-carotene Substances 0.000 claims description 3
- 229960002747 betacarotene Drugs 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 230000007423 decrease Effects 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 40
- 239000000243 solution Substances 0.000 description 24
- 239000004480 active ingredient Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 108010044426 integrins Proteins 0.000 description 8
- 102000006495 integrins Human genes 0.000 description 8
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 7
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 7
- 239000011565 manganese chloride Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000003416 augmentation Effects 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 description 4
- WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 description 4
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000002304 perfume Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 108010028309 kalinin Proteins 0.000 description 3
- 229940099607 manganese chloride Drugs 0.000 description 3
- 235000002867 manganese chloride Nutrition 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 244000281702 Dioscorea villosa Species 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 229920002230 Pectic acid Polymers 0.000 description 2
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 235000004879 dioscorea Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 210000000301 hemidesmosome Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 239000010318 polygalacturonic acid Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000009919 sequestration Effects 0.000 description 2
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N trilaurin Chemical compound CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- WTVHAMTYZJGJLJ-LSDHHAIUSA-N β-bisabolol Chemical compound CC(C)=CCC[C@H](C)[C@]1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-LSDHHAIUSA-N 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- IGSYEZFZPOZFNC-UHFFFAOYSA-N 4-O-alpha-D-Galactopyranuronosyl-D-galacturonic acid Natural products OC1C(O)C(O)OC(C(O)=O)C1OC1C(O)C(O)C(O)C(C(O)=O)O1 IGSYEZFZPOZFNC-UHFFFAOYSA-N 0.000 description 1
- FMNDXLWVYMQMHF-UHFFFAOYSA-N 6-[2-carboxy-6-(1-carboxy-1,3,4-trihydroxy-5-oxopentan-2-yl)oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound OC1C(O)C(OC(C(O)C(C=O)O)C(O)C(O)=O)OC(C(O)=O)C1OC1C(O)C(O)C(O)C(C(O)=O)O1 FMNDXLWVYMQMHF-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- -1 Cetyl stearic alcohol Chemical compound 0.000 description 1
- 244000258136 Costus speciosus Species 0.000 description 1
- 235000000385 Costus speciosus Nutrition 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 235000005903 Dioscorea Nutrition 0.000 description 1
- 235000000504 Dioscorea villosa Nutrition 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010030506 Integrin alpha6beta4 Proteins 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 244000141359 Malus pumila Species 0.000 description 1
- 108010009711 Phalloidine Proteins 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 235000016127 added sugars Nutrition 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-UHFFFAOYSA-N alpha-D-Galacturono-tri-saccharide Natural products OC1C(O)C(O)OC(C(O)=O)C1OC1C(O)C(O)C(OC2C(C(O)C(O)C(O2)C(O)=O)O)C(C(O)=O)O1 LCLHHZYHLXDRQG-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- AEMOLEFTQBMNLQ-DTEWXJGMSA-N beta-D-galacturonic acid Polymers O[C@@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-DTEWXJGMSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940074775 beta-bisabolol Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- ALSTYHKOOCGGFT-UHFFFAOYSA-N cis-oleyl alcohol Natural products CCCCCCCCC=CCCCCCCCCO ALSTYHKOOCGGFT-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004692 intercellular junction Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000003375 plant hormone Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229950006451 sorbitan laurate Drugs 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 229930000053 β-bisabolol Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Definitions
- This invention relates to new cosmetic compositions for skin care with an antiaging intent. More particularly, the invention pertains to the cosmetic use of a mixture of oligosaccharides of the type obtained by enzymatic hydrolysis of a pectin.
- the oligosaccharides stimulate adhesion of keratinocytes to proteins of the dermoepidermal junction (laminin V and collagen IV).
- the compositions of the invention can resolve disturbances in communication between the dermis and the epidermis and the decrease in the interkeratinocyte cohesion within the epidermis that appear during cutaneous aging and thereby restore epidermal cohesion.
- the basal membrane of the skin or dermoepidermal junction corresponds to the zone comprised anatomically between the basal cells of the epidermis and the more superficial layers of the dermis. This is a zone of adherence between the epidermis and the dermis, providing for the control of the filtration of small molecules and the maintenance of the adjacent cells (Damour O., M. C. Martini and P. Rousselle, October 1998, Cutaneous Aging, pub. Flash Media).
- the DEJ comprises specific attachment complexes, the hemidesmosomes, whose function is to provide a bond between basal keratinocytes of the epidermis and the subjacent basal membrane (Kelly, 1966, J. Cell. Biol., 28: 51-73).
- the DEJ plays a very important role both on the mechanical level, since it enables solid anchoring of the epidermis, as well as on the biological level, since it intervenes in cell signalization via the integrin family of receptors.
- Integrins are transmembranal glycoproteins located on the basal part of the keratinocyte in contact with the DEJ. They have an extracellular part enabling recognition with the characteristic proteins of the DEJ.
- laminin V which is a constitutive protein of the hemidesmosomes, and collagen IV.
- These proteins via the membrane receptors (the ⁇ 6 ⁇ 4 ⁇ 3 ⁇ 1 integrins for laminin V and the ⁇ 2 ⁇ 1 integrins for collagen IV), enable: adhesion of the basal keratinocytes to the support according to a clearly defined orientation, and transmission of signals from the dermis to the epidermis as proliferation signals, differentiation of the keratinocytes.
- These integrins are, thus, veritable zones of dialogue between the interior and the exterior of the cell and beyond that of the basal layer, they contribute, by promoting cellular adhesion to better communication between the principal compartments of the skin, the dermis and the epidermis.
- This invention relates to a dermatological composition including a therapeutically effective amount of an agent stimulating adherence of basal keratinocytes to laminin V and/or collagen IV that reduces communication disturbances between a subject's dermis and epidermis and reduces diminishment in interkeratinocyte cohesion within the epidermis.
- This invention also relates to a method of preparing oligogalacturonides including hydrolysis of a pectin solution at a concentration of about 0.1 to about 10% at an acidic pH, by addition to the pectin solution of an enzyme solution of about 10 to about 1000 polygalacturonase units to obtain in a final solution of about 1 to about 10 pectinase units; stopping the hydrolysis; separation of resulting high-molecular-weight polymers from the final solution; and recovery of the oligogalacturonides.
- This invention further relates to a method of preventing aging of skin including applying a therapeutically effective amount of the composition stimulating adherence of basal keratinocytes to laminin V and/or collagen IV that resolves communication disturbances between a subject's dermis and epidermis and diminishment in interkeratinocyte cohesion within the epidermis to the skin.
- This invention still further relates to a method of reducing decreases in interkeratinocyte cohesion is skin including applying a therapeutically effective amount of the composition stimulating adherence of basal keratinocytes to laminin V and/or collagen IV that resolves communication disturbances between a subject's dermis and epidermis and diminishment in interkeratihocyte cohesion within the epidermis to the skin.
- FIGS. 1A and 1B are photographs showing the number of cells adhered to laminin V.
- FIG. 1A is a control and FIG. 1B is in accordance with aspects of the invention.
- FIGS. 2A and 2B are photographs showing the number of cells adhered to collagen IV.
- FIG. 2A is a control and FIG. 2B is in accordance with aspects of the invention.
- This invention relates to a means of cosmetic or dermatological compositions for skin care and, more particularly, for combating aging of the skin, comprising oligogalacturonides as an active ingredient.
- Application of the composition according to aspects of the invention promotes adhesion of cells to two proteins of the DEJ by an enhanced availability of the ⁇ 6 ⁇ 4 receptors for laminin V and the ⁇ 2 ⁇ 1 receptors for collagen IV.
- the composition according to aspects of the invention induces activation of these receptors by means of a change of conformation.
- the oligogalacturonides of the compositions according to the invention preferably have a degree of polymerization between about 1 and about 5.
- the oligogalacturonides of the compositions according to the invention are at least partially methylated or esterified.
- the cosmetic compositions of the invention comprise, in dry equivalent in relation to the total weight of the composition, from about 0.01 to about 5%, preferably about 0.5%, of oligogalacturonides.
- the cosmetic compositions of the invention can also comprise other active substances, more specifically plant extracts.
- extracts include: a yam extract (Dioscorea) with a content of diosgenin or pure diosgenin. This can be an extract containing about 15% of diosgenin or a solution of pure diosgenin; and pure or diluted beta carotene in the form of a suspension in oil, notably, a about 30% dilution.
- compositions according to the invention can also comprise one or more formulation agents or additives of common and conventional use in cosmetic and dermatological compositions such as, as nonlimitative examples, softeners, colorants, film-forming agents, surface-active agents, perfumes, preservatives, emulsifiers, oils, glycols, sebum-absorbing agents, vitamins and the like.
- formulation agents or additives of common and conventional use in cosmetic and dermatological compositions such as, as nonlimitative examples, softeners, colorants, film-forming agents, surface-active agents, perfumes, preservatives, emulsifiers, oils, glycols, sebum-absorbing agents, vitamins and the like.
- compositions according to the invention can be made available in any form known in art of cosmetology and dermatology without any pharmaceutical restriction other than application to the skin of the face or the body.
- the compositions according to the invention are advantageously presented in the form of a gel, a cream, an emulsion, a milk, a spray and the like.
- the oligogalacturonides of the compositions according to the invention are advantageously obtained by enzymatic hydrolysis of a pectin.
- Pectin is constituted of a principal chain called “pectic acid” comprising a chain of galacturonic acid type sugars.
- the constitutive sugars can be methylated or esterified, and the proportion of transformed sugars is characteristic of a plant species.
- the principal chain is sometimes interrupted by the insertion of a side chain of neutral sugars such as rhamnose or glucose.
- oligogalacturonides previously referred to as oligosaccharines, have been described as veritable plant hormones (Darvill et al., Glycobiology, vol. 2, no. 3 , pp 181-198, 1992). They can be prepared by hydrolysis of pectin; the size or degree of polymerization of the oligogalacturonides is a function of the conditions of the hydrolysis reaction.
- oligogalacturonides providing an industrial product that is effective as a cosmetic agent.
- Numerous pectins are available commercially in large quantity and variable quality. These are often standardized pectins that frequently contain added sugars to enable homogenization of the viscosities among the batches. In fact, the first use of these pectins is linked to their gelling properties and as viscosity agents.
- the oligogalacturonides employed in the compositions of the invention are preferably prepared by hydrolysis of pectin having a low degree of methylation and esterification to be as close as possible to polygalacturonic acid.
- pectin type HB AU The pectins of the type HERBSTREITH and FOX Classic AU 910 obtained from apples (pectin type HB AU) are an example of such a pectin.
- the enzymes used for the hydrolysis of pectin are of the industrial type frequently used in the fruit juice processing industry. These are cocktails of enzymes conceived to cut the membranal pectins and thereby enable better extraction of the fruit juices by making the structures fragile prior to pressing. They also make possible clarification of the juices in which turbidity—often linked to pectins—is not desirable.
- the enzyme marketed by the company LYVEN as Clarification granulated is an example of such an enzyme.
- the enzyme cocktail comprises pectinases having principally polygalacturonase, methyl esterase and polygalacturonase lyase activities.
- a preferred method for preparing oligogalacturonides according to the invention comprises the following steps:
- the hydrolysis is advantageously performed at about 50° C. for about 2 hours then stopped by heating at about 70° C. for about 1 hour or at about 100° C. for about 5 minutes.
- the high-molecular-weight polymers are preferably precipitated by addition of HCl 1N then eliminated by centrifugation, e.g., at about 5000 g for about 30 minutes or by filtration.
- the pH of the supernatant is then readjusted to a value between about 6 and about 8, e.g., on the order of about 6.9.
- the invention also relates the use in cosmetics or for the preparation of a pharmaceutical composition, notably a dermatological composition, of oligogalacturonides as defined above as an agent stimulating adherence of the basal keratinocytes to the two major proteins of the DEJ, which are laminin V and collagen IV, and resolve the disturbances of communication between the dermis and the epidermis, and the diminishment in the interkeratinocyte cohesion within the epidermis, which appear during cutaneous aging.
- a pharmaceutical composition notably a dermatological composition, of oligogalacturonides as defined above as an agent stimulating adherence of the basal keratinocytes to the two major proteins of the DEJ, which are laminin V and collagen IV, and resolve the disturbances of communication between the dermis and the epidermis, and the diminishment in the interkeratinocyte cohesion within the epidermis, which appear during cutaneous aging.
- the invention also pertains to a cosmetic method for resolving the disturbances in communication between the dermis and the epidermis, and the diminishment in interkeratinocyte cohesion within the epidermis, which appear during cutaneous aging and thereby to restore the epidermis cohesion comprising applying to the skin a therapeutically effective amount of oligogalacturonides or of a composition containing them as defined above.
- Pectin put in solution at from 0.1 to 10% (1% of pectin HB AU910).
- the pH is adjusted to 4.5, preferably with an acetic acid solution.
- Enzyme A solution is prepared corresponding to 10 to 1000, preferably 100, polygalacturonase units. The enzymatic solution is added to the pectin solution to obtain at the end a solution of 1 to 10, preferably 4, pectinase units. Hydrolysis is performed at 50° C. for 2 hours then stopped by heating at 70° C. for 1 hour or at 100° C. for 5 minutes. After cooling, the high-molecular-weight polymers are precipitated by addition of HCl 1N then eliminated by centrifugation, e.g., at 5000 g for 30 minutes or by filtration. The pH of the supernatant is readjusted at the end to a value comprised between 6 and 8, e.g., on the order of 6.9.
- the oligogalacturonides formed are advantageously atomized or lyophilized at the end to enable better preservation and easier handling.
- Oven temperature 130° C.
- Nitrogen flow rate 4.0 SLPM (standard liter per minute): standard conditions for H 2 O as solvent.
- the culture medium employed was the defined medium for keratinocyte culture 154 (+additive HKGS) manufactured by Cascade Inc. (USA) and marketed by Tebu (France) containing 0.2 mM of CaCl 2 , pH 7.2 to 7.4.
- the keratinocytes were obtained according to the technique described by Boyce and Ham (Boyce S T, Ham R G, J. Invest. Dermatol., 1983, 81, 33s-40s). Pieces of human skin obtain from human prepuces (circumcision) were treated in a manner to isolate their basal human keratinocytes. 3 ⁇ 10 4 live cells were then seeded per cm 2 on 25-cm 2 tissue culture dishes (Coming, Polylabo, France).
- the keratinocytes were cultured at 37° C. in an incubator with CO 2 (5% of CO 2 , 95% of air and 98% humidity). The medium was changed every two days. Subculture took place when the cells reached subconfluence. The cell layer was then rinsed with PBS, then the cells were trypsinated using the conventional trypsination technique (Trypsin-EDTA (0.05-0.02%) at 37° C.). The cells were then seeded in 75-cm 2 culture dishes.
- CO 2 5% of CO 2 , 95% of air and 98% humidity
- Freezing the cells 3 to 5 million per ampoule, was performed in the culture medium employed, in the presence of 10% dimethyl sulfoxide (DMSO) and 20% of calf serum in a volume of 1 ml.
- DMSO dimethyl sulfoxide
- a dose-response for each of the adhesion substrates was determined to establish the ideal concentration of the adherence proteins that will subsequently be used.
- Collagen IV (Becton Dickinson, France), fibronectin (Becton Dickinson, France) and laminin 5 , purified in the laboratory (Pousselle P. et al., J. Cell. Biol., 1991, 114(3); 567-576) were used in our experiments.
- a range of seven decreasing concentrations was created by successive dilution in distilled water, from a starting solution of 10 ⁇ g/ml. These solutions were immediately distributed on 96-well culture plates (Costar, Dutscher, Brumath, France) at the rate of 100 ⁇ g per well. The plates were then placed at +4° C. for 16 to 18 hours. The solutions were then removed by turning over the plates and each well was saturated by an aqueous solution of SAB 1% (3 supplementary wells without substrate were subjected to the same treatment and functioned as blanks).
- the cells were trypsinated as described above, then suspended in the medium 154 without additives (3 ⁇ 10 5 cells/ml) then seeded in passage 2 in multiwell plates of 100 ⁇ l/well.
- the multiwell plates were placed in an incubator at 37° C. for a duration of 45 minutes in the presence of or absence of the oligogalacturonide mixture at different noncytotoxic concentrations in the culture medium.
- a positive control was implemented in parallel (manganese chloride (0.5 mM)) to validate the experiment. After incubation, the cells were observed with a phase-contrast microscope to verify that the test had taken place correctly.
- Manganese chloride (0.5 mM) was used as a positive control for the adhesion of the cells to the substrate.
- the adherence result obtained with the cells without active ingredient and without positive control was set arbitrarily at 100%.
- the active ingredient identified here constitutes the reference solution of oligosaccharides type oligo G04 (not lyophilized).
- Manganese chloride (0.5 mM) was used as positive control for the adhesion of the cells to the substrate.
- the adherence results obtained with the cells without active ingredient and without positive control was set arbitrarily at 100%.
- FIGS. 1A and 1B show that, in the presence of the active ingredient used at 0.01% (FIG. 1B), the number of cells having adhered to laminin V was greater than in the control (FIG. 1A). These cells are more spread apart and the representative actin network of the cellular cytoskeleton is much better organized. These morphological changes due to the presence of the active ingredient (compared to the control) indicate that this ingredient truly promotes the recruitment and activation of the integrin ⁇ 6 ⁇ 4.
- the oligogalacturonides can be incorporated at the rate of about 0.1 to about 5%, preferably at the rate of about 0.5%.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
Abstract
A dermatological composition including a therapeutically effective amount of an agent stimulating adherence of basal keratinocytes to laminin V and/or collagen IV that resolves communication disturbances between a subject's dermis and epidermis and diminishment in interkeratinocyte cohesion within the epidermis.
Description
- This is a continuation of International Application No. PCT/FR02/03844, with an international filing date of Nov. 8, 2002 (WO 03/039509, published May 15, 2003), which is based on French Patent Application No. 01/14463, filed Nov. 8, 2001.
- This invention relates to new cosmetic compositions for skin care with an antiaging intent. More particularly, the invention pertains to the cosmetic use of a mixture of oligosaccharides of the type obtained by enzymatic hydrolysis of a pectin. The oligosaccharides stimulate adhesion of keratinocytes to proteins of the dermoepidermal junction (laminin V and collagen IV). The compositions of the invention can resolve disturbances in communication between the dermis and the epidermis and the decrease in the interkeratinocyte cohesion within the epidermis that appear during cutaneous aging and thereby restore epidermal cohesion.
- The basal membrane of the skin or dermoepidermal junction (DEJ) corresponds to the zone comprised anatomically between the basal cells of the epidermis and the more superficial layers of the dermis. This is a zone of adherence between the epidermis and the dermis, providing for the control of the filtration of small molecules and the maintenance of the adjacent cells (Damour O., M. C. Martini and P. Rousselle, October 1998, Cutaneous Aging, pub. Flash Media).
- The DEJ comprises specific attachment complexes, the hemidesmosomes, whose function is to provide a bond between basal keratinocytes of the epidermis and the subjacent basal membrane (Kelly, 1966, J. Cell. Biol., 28: 51-73). The DEJ plays a very important role both on the mechanical level, since it enables solid anchoring of the epidermis, as well as on the biological level, since it intervenes in cell signalization via the integrin family of receptors.
- Integrins are transmembranal glycoproteins located on the basal part of the keratinocyte in contact with the DEJ. They have an extracellular part enabling recognition with the characteristic proteins of the DEJ. Among the components of the DEJ, we can cite two proteins which play a fundamental role within the DEJ: laminin V, which is a constitutive protein of the hemidesmosomes, and collagen IV.
- These proteins, via the membrane receptors (the α6β4 α3β1 integrins for laminin V and the α2β1 integrins for collagen IV), enable: adhesion of the basal keratinocytes to the support according to a clearly defined orientation, and transmission of signals from the dermis to the epidermis as proliferation signals, differentiation of the keratinocytes. These integrins are, thus, veritable zones of dialogue between the interior and the exterior of the cell and beyond that of the basal layer, they contribute, by promoting cellular adhesion to better communication between the principal compartments of the skin, the dermis and the epidermis.
- More recently, it has been shown that adhesion of the basal keratinocytes to the major proteins of the DEJ, such as laminin V, collagen IV and fibronectin, appears to regulate the expression of the junctions (junction gap) between the keratinocytes of the epidermis (Lampe et al., J. Cell. Biol., 1998, 1735-1747). Thus, an increase in the interactions between especially laminin V and the basal keratinocytes via integrins such as α6β4 α3β1 generates the emission of signals within the epidermis to promote formation of intercellular junctions and enable better communication among keratinocytes of the epidermis.
- During cutaneous aging, there is seen a flatting and a thinning of the DEJ. The adherence properties of the epidermis are decreased because of a diminishment in the expression of the integrins specifically involved in the adhesion of the basal keratinocytes (Levarlet et al., 1998, J. Invest. Dermatol., 3: 172-9). All of these changes lead to a diminishment in communication between the various compartments, probably contributing to dermoepidermal disorganization.
- Even though not all of the mechanisms have been clarified, everything leads one to believe that an augmentation of the adherence of the cells, especially to the DEJ, enables reestablishment of better dermoepidermal communication as well as better epidermal cohesion leading to the restoration of a better coordination of the functions of the skin. In fact, disturbances in the dermoepidermal communication, on the one hand, and at the level of the cohesion among the keratinocytes of the epidermis, on the other hand, could lead to disturbances in coordination of the cell functions such as proliferation and/or epidermal differentiation.
- It would, therefore, be advantageious to provide means enabling augmentation specifically of the adherence of basal keratinocytes to the two major proteins of the DEJ, which are laminin V and collagen IV, to resolve disturbances in communication between the dermis and the epidermis, and diminishment in interkeratinocyte cohesion that appear during cutaneous aging.
- This invention relates to a dermatological composition including a therapeutically effective amount of an agent stimulating adherence of basal keratinocytes to laminin V and/or collagen IV that reduces communication disturbances between a subject's dermis and epidermis and reduces diminishment in interkeratinocyte cohesion within the epidermis.
- This invention also relates to a method of preparing oligogalacturonides including hydrolysis of a pectin solution at a concentration of about 0.1 to about 10% at an acidic pH, by addition to the pectin solution of an enzyme solution of about 10 to about 1000 polygalacturonase units to obtain in a final solution of about 1 to about 10 pectinase units; stopping the hydrolysis; separation of resulting high-molecular-weight polymers from the final solution; and recovery of the oligogalacturonides.
- This invention further relates to a method of preventing aging of skin including applying a therapeutically effective amount of the composition stimulating adherence of basal keratinocytes to laminin V and/or collagen IV that resolves communication disturbances between a subject's dermis and epidermis and diminishment in interkeratinocyte cohesion within the epidermis to the skin.
- This invention still further relates to a method of reducing decreases in interkeratinocyte cohesion is skin including applying a therapeutically effective amount of the composition stimulating adherence of basal keratinocytes to laminin V and/or collagen IV that resolves communication disturbances between a subject's dermis and epidermis and diminishment in interkeratihocyte cohesion within the epidermis to the skin.
- FIGS. 1A and 1B are photographs showing the number of cells adhered to laminin V. FIG. 1A is a control and FIG. 1B is in accordance with aspects of the invention.
- FIGS. 2A and 2B are photographs showing the number of cells adhered to collagen IV. FIG. 2A is a control and FIG. 2B is in accordance with aspects of the invention.
- This invention relates to a means of cosmetic or dermatological compositions for skin care and, more particularly, for combating aging of the skin, comprising oligogalacturonides as an active ingredient. Application of the composition according to aspects of the invention promotes adhesion of cells to two proteins of the DEJ by an enhanced availability of the α6β4 receptors for laminin V and the α2β1 receptors for collagen IV. The composition according to aspects of the invention induces activation of these receptors by means of a change of conformation.
- The oligogalacturonides of the compositions according to the invention preferably have a degree of polymerization between about 1 and about 5. The oligogalacturonides of the compositions according to the invention are at least partially methylated or esterified. The cosmetic compositions of the invention comprise, in dry equivalent in relation to the total weight of the composition, from about 0.01 to about 5%, preferably about 0.5%, of oligogalacturonides.
- In addition to the oligogalacturonides, the cosmetic compositions of the invention can also comprise other active substances, more specifically plant extracts. Examples of such extracts include: a yam extract (Dioscorea) with a content of diosgenin or pure diosgenin. This can be an extract containing about 15% of diosgenin or a solution of pure diosgenin; and pure or diluted beta carotene in the form of a suspension in oil, notably, a about 30% dilution.
- The compositions according to the invention can also comprise one or more formulation agents or additives of common and conventional use in cosmetic and dermatological compositions such as, as nonlimitative examples, softeners, colorants, film-forming agents, surface-active agents, perfumes, preservatives, emulsifiers, oils, glycols, sebum-absorbing agents, vitamins and the like. Those skilled in the art know which formulation agents to add to the compositions of the invention and what amounts in relation to the desired properties.
- The compositions according to the invention can be made available in any form known in art of cosmetology and dermatology without any pharmaceutical restriction other than application to the skin of the face or the body. The compositions according to the invention are advantageously presented in the form of a gel, a cream, an emulsion, a milk, a spray and the like.
- The oligogalacturonides of the compositions according to the invention are advantageously obtained by enzymatic hydrolysis of a pectin. Pectin is constituted of a principal chain called “pectic acid” comprising a chain of galacturonic acid type sugars. The constitutive sugars can be methylated or esterified, and the proportion of transformed sugars is characteristic of a plant species. The principal chain is sometimes interrupted by the insertion of a side chain of neutral sugars such as rhamnose or glucose.
- The oligogalacturonides, previously referred to as oligosaccharines, have been described as veritable plant hormones (Darvill et al., Glycobiology, vol. 2, no.3, pp 181-198, 1992). They can be prepared by hydrolysis of pectin; the size or degree of polymerization of the oligogalacturonides is a function of the conditions of the hydrolysis reaction.
- We have now developed a method for preparing oligogalacturonides providing an industrial product that is effective as a cosmetic agent. Numerous pectins are available commercially in large quantity and variable quality. These are often standardized pectins that frequently contain added sugars to enable homogenization of the viscosities among the batches. In fact, the first use of these pectins is linked to their gelling properties and as viscosity agents. The oligogalacturonides employed in the compositions of the invention are preferably prepared by hydrolysis of pectin having a low degree of methylation and esterification to be as close as possible to polygalacturonic acid.
- The pectins of the type HERBSTREITH and FOX Classic AU 910 obtained from apples (pectin type HB AU) are an example of such a pectin. The enzymes used for the hydrolysis of pectin are of the industrial type frequently used in the fruit juice processing industry. These are cocktails of enzymes conceived to cut the membranal pectins and thereby enable better extraction of the fruit juices by making the structures fragile prior to pressing. They also make possible clarification of the juices in which turbidity—often linked to pectins—is not desirable. The enzyme marketed by the company LYVEN as Clarification granulated is an example of such an enzyme. The enzyme cocktail comprises pectinases having principally polygalacturonase, methyl esterase and polygalacturonase lyase activities.
- A preferred method for preparing oligogalacturonides according to the invention comprises the following steps:
- hydrolysis of a pectin solution at a concentration of about 0.1 to about 10%, preferably at about 1%, at a pH of about 4.5, by addition to the pectin solution of an enzyme solution comprising from about 10 to about 1000, preferably about 100, polygalacturonase units to obtain in the final solution from about 1 to about 10, preferably about 4, pectinase units;
- stopping the hydrolysis; and
- separation of the high-molecular-weight polymers and recovery of the oligogalacturonides.
- The hydrolysis is advantageously performed at about 50° C. for about 2 hours then stopped by heating at about 70° C. for about 1 hour or at about 100° C. for about 5 minutes. After cooling, the high-molecular-weight polymers are preferably precipitated by addition of HCl 1N then eliminated by centrifugation, e.g., at about 5000 g for about 30 minutes or by filtration. The pH of the supernatant is then readjusted to a value between about 6 and about 8, e.g., on the order of about 6.9.
- The invention also relates the use in cosmetics or for the preparation of a pharmaceutical composition, notably a dermatological composition, of oligogalacturonides as defined above as an agent stimulating adherence of the basal keratinocytes to the two major proteins of the DEJ, which are laminin V and collagen IV, and resolve the disturbances of communication between the dermis and the epidermis, and the diminishment in the interkeratinocyte cohesion within the epidermis, which appear during cutaneous aging.
- The invention also pertains to a cosmetic method for resolving the disturbances in communication between the dermis and the epidermis, and the diminishment in interkeratinocyte cohesion within the epidermis, which appear during cutaneous aging and thereby to restore the epidermis cohesion comprising applying to the skin a therapeutically effective amount of oligogalacturonides or of a composition containing them as defined above.
- Other advantages and characteristics of the invention will emerge from the examples below concerning the preparation of oligogalacturonides and their use as cosmetic agent.
- I. Preparation of the oligogalacturonides
- 1) Operating procedure
- Pectin: put in solution at from 0.1 to 10% (1% of pectin HB AU910).
- The pH is adjusted to 4.5, preferably with an acetic acid solution.
- Enzyme: A solution is prepared corresponding to 10 to 1000, preferably 100, polygalacturonase units. The enzymatic solution is added to the pectin solution to obtain at the end a solution of 1 to 10, preferably 4, pectinase units. Hydrolysis is performed at 50° C. for 2 hours then stopped by heating at 70° C. for 1 hour or at 100° C. for 5 minutes. After cooling, the high-molecular-weight polymers are precipitated by addition of HCl 1N then eliminated by centrifugation, e.g., at 5000 g for 30 minutes or by filtration. The pH of the supernatant is readjusted at the end to a value comprised between 6 and 8, e.g., on the order of 6.9.
- The oligogalacturonides formed are advantageously atomized or lyophilized at the end to enable better preservation and easier handling.
- 2) HPLC anaylsis of the oligogalacturonides formed
- An analysis technique producing a chromatographic profile of the oligogalacturonides formed was developed.
- Column: TSK gel DEAE 5-PW (TOSOHAAS)
- Eluent: CH3COONH4 1M/H2O in elution gradient
- Mobile phase flow rate: 1 ml/min
- Light diffusion evaporative detector (DEDL; ALTECH).
- Oven temperature: 130° C.
- Nitrogen flow rate: 4.0 SLPM (standard liter per minute): standard conditions for H2O as solvent.
- The selection of the gradient is presented in Table 1 below:
TABLE 1 Time in minutes % A (CH3COONH4 1M) % B (H2O) 0 10 90 1 30 70 3 30 70 30 50 50 45 50 50 - We observe a distribution of the oligomers by size (dp: degree of polymerization) from 1 to 5.
- The absence of a standard does not allow quantitative determination of the oligomers of dp 4 and 5, but quantitative determination of the shorter oligomers is possible.
- If we proceed according to the conditions described for hydrolysis of a pectin solution of conentration 10 g/l, the total concentration in mono-, di- and trigalacturonic acid is approximately 4.5 g/l at the end, thus approximately 45% by weight of the pectin put in solution.
- II. Effects of the Oligogalacturonides on the Adhesion of Human Keratinocytes to Laminin V and to Collagen IV
- 1) Material and Methods
- a) Culture of the Keratinocytes in Defined Medium
- The culture medium employed was the defined medium for keratinocyte culture154 (+additive HKGS) manufactured by Cascade Inc. (USA) and marketed by Tebu (France) containing 0.2 mM of CaCl2, pH 7.2 to 7.4.
- The keratinocytes were obtained according to the technique described by Boyce and Ham (Boyce S T, Ham R G, J. Invest. Dermatol., 1983, 81, 33s-40s). Pieces of human skin obtain from human prepuces (circumcision) were treated in a manner to isolate their basal human keratinocytes. 3·104 live cells were then seeded per cm2 on 25-cm2 tissue culture dishes (Coming, Polylabo, France).
- The keratinocytes were cultured at 37° C. in an incubator with CO2 (5% of CO2, 95% of air and 98% humidity). The medium was changed every two days. Subculture took place when the cells reached subconfluence. The cell layer was then rinsed with PBS, then the cells were trypsinated using the conventional trypsination technique (Trypsin-EDTA (0.05-0.02%) at 37° C.). The cells were then seeded in 75-cm2 culture dishes.
- Freezing the cells, 3 to 5 million per ampoule, was performed in the culture medium employed, in the presence of 10% dimethyl sulfoxide (DMSO) and 20% of calf serum in a volume of 1 ml.
- b) Quantitative Analysis of Cellular Adherence by a Calorimetric Test
- Preparation of the Adherence Substrates
- A dose-response for each of the adhesion substrates was determined to establish the ideal concentration of the adherence proteins that will subsequently be used.
- Collagen IV (Becton Dickinson, France), fibronectin (Becton Dickinson, France) and laminin5, purified in the laboratory (Pousselle P. et al., J. Cell. Biol., 1991, 114(3); 567-576) were used in our experiments. A range of seven decreasing concentrations was created by successive dilution in distilled water, from a starting solution of 10 μg/ml. These solutions were immediately distributed on 96-well culture plates (Costar, Dutscher, Brumath, France) at the rate of 100 μg per well. The plates were then placed at +4° C. for 16 to 18 hours. The solutions were then removed by turning over the plates and each well was saturated by an aqueous solution of SAB 1% (3 supplementary wells without substrate were subjected to the same treatment and functioned as blanks).
- Test of Cellular Adherence
- The cells were trypsinated as described above, then suspended in the medium154 without additives (3×105 cells/ml) then seeded in passage 2 in multiwell plates of 100 μl/well.
- Evaluation of the Cellular Adherence Test
- After seeding of the cells, the multiwell plates were placed in an incubator at 37° C. for a duration of 45 minutes in the presence of or absence of the oligogalacturonide mixture at different noncytotoxic concentrations in the culture medium. A positive control was implemented in parallel (manganese chloride (0.5 mM)) to validate the experiment. After incubation, the cells were observed with a phase-contrast microscope to verify that the test had taken place correctly.
- The characteristic spread of the keratinocytes on laminin5 (Rousselle P. and Aumilley M., J. Cell. Biol., 1994, 125(1): 205-214) was taken into account. After rinsing, the remaining cells, adherent to the substrate, were fixed with a 1% glutaraldehyde solution in PBS for 15 minutes. After elimination of the fixative, the cells were stained with a crystal violet solution diluted to 1% in distilled water for 30 minutes. After intensive rinsing with water, the cells were permeabilized with a 0.02% triton solution for 15 minutes to solubilize the crystal violet.
- An absorbance reading was performed at 570 nm using an ELISA plate reader. Each experimental point was performed in three samples. The blank value represents the mean of the absorbance of 3 control wells (BSA). This value was subtracted from each of the optical density values obtained for the experimental points. We then calculated the means of the three absorbance values for each of the triplicates.
- 2) Results
- a) Study of the Adhesion of Normal Human Keratinocytes on Laminin V
- Manganese chloride (0.5 mM) was used as a positive control for the adhesion of the cells to the substrate. The adherence result obtained with the cells without active ingredient and without positive control was set arbitrarily at 100%. The active ingredient identified here constitutes the reference solution of oligosaccharides type oligo G04 (not lyophilized).
- The results obtained are presented in Table 2 below.
TABLE 2 Laminin 5 Laminin 5 3 μg/ml % SD 1.5 μg/ml % SD Cells alone 100 Cells alone 100 MnCl2 97 6.4 MnCl2 109 5.1 Solvent 101 0.96 Solvent 107 7.9 Active 5% 103 0.16 Active 5% 119 1.4 1% 116 14 1% 100 7.5 0.01% 105 7.2 0.01% 105 7.5 - The mixture induced an augmentation of 116% on laminin V at the concentration of 1%.
- b) Study of the Adhesion of Normal Human Keratinocytes on Collagen IV
- Manganese chloride (0.5 mM) was used as positive control for the adhesion of the cells to the substrate. The adherence results obtained with the cells without active ingredient and without positive control was set arbitrarily at 100%.
- The results obtained are presented in Table 3 below.
TABLE 3 Collagen IV Collagen IV 20 μg/ml % SD 10 μg/ml % SD Cells alone 100 Cells alone 100 MnCl2 357 29 MnCl2 280 10 Solvent 105 2.3 Solvent 90 3 Active 5% 84 4.7 Active 5% 66 6 1% 126 17 1% 90 15 0.01% 101 5.9 0.01% 80 2.5 - The mixture induced an augmentation of 126% on collagen IV at the concentration of 1%.
- c) Study of the Morphology of Normal Human Keratinocytes after Adhesion on Laminin V or Collagen IV
- Visualization of the spread and form of the adhered cells was performed by a demonstration of the cytoskeleton of actin by performing immunolabeling with phalloidin coupled to FITC.
- Adhesion to Laminin V
- FIGS. 1A and 1B show that, in the presence of the active ingredient used at 0.01% (FIG. 1B), the number of cells having adhered to laminin V was greater than in the control (FIG. 1A). These cells are more spread apart and the representative actin network of the cellular cytoskeleton is much better organized. These morphological changes due to the presence of the active ingredient (compared to the control) indicate that this ingredient truly promotes the recruitment and activation of the integrin α6β4.
- Adhesion to Collagen IV
- In the absence (FIG. 2A) or in the presence of the active ingredient (FIG. 2B), the cells adhere to collagen IV. However, it can be seen that in the presence of the active ingredient (FIG. 2B), the cells are larger, with a rather rounded shape with a very good cortical organization of the actin. In this case, the cells are joined, pressed against each other, indicating that the active ingredient stimulates cell-cell contacts and intercellular cohesion.
- In conclusion, augmentation of the adherence of cells to laminin V in the presence of the active ingredient appears to come about via an augmentation of the expression of α6β4. The morphology and the spread of the cells on collagen IV in the presence of the active ingredient indicates that there is produced a recruitment of integrins α2β1 (specific to collagen IV) and that there also exists an enhanced cohesion among the keratinocytes.
- III. Incorporation in a Cosmetic Formulation
- In dry equivalents, the oligogalacturonides can be incorporated at the rate of about 0.1 to about 5%, preferably at the rate of about 0.5%.
- 1) Example of Composition in Emulsion Form
Water QSP Oligogalacturonides dp 1 to 5 (dry matter) 0.01 to 5% Mixture of preservatives 1.5% Propylene glycol 5.00% Xanthan gum 0.30% Acrylic/acrylate copolymer 0.50% Stearic acid 100 OE** 3.00% Sorbitan stearate 2.00% Sorbitan laurate 20 OE 3.00% Cetyl stearic alcohol 1.50% Bee's wax 1.00% Wheat germ oil 5.00% Dimethicone 2.00% Cyclomethicone 5.00% Polyacrylamide gel 2.00% Perfume 0.10% - 2) Example of Composition in Cream Form
Water QSP Oligogalacturonides dp 1 to 5 (dry matter) 0.001% to 0.1% Xanthan gum 0.30% Sequestration agent (e.g., EDTA) 0.05% Preservatives 1.50% Acid C18 2.50% Acid C16 2.50% Trilaurin 1.00% Shea butter 3.00% Tocopherol acetate 0.05% β-bisabolol 0.05% Vegetable oil (wheat germ) 5.00% Dimethicone 3.00% Polyacrylic acid 0.30% TEA (triethanolamine) 1.50% Perfume 0.10% - 3) Example of Composition in Lotion Form
Water QSP Oligogalacturonides dp 1 to 5 (dry matter) 0.001 to 0.1% Sequestration agent 0.05% Propylene glycol 2.00% Mixture of preservatives 1.5% Alcohol 5 to 50% Oleic alcohol 20 OE 1.00% Perfume 0.05%
Claims (21)
1. A dermatological composition comprising:
a therapeutically effective amount of an agent stimulating adherence of basal keratinocytes to laminin V and/or collagen IV that reduces communication disturbances between a subject's dermis and epidermis and reduces diminishment in interkeratinocyte cohesion within the epidermis.
2. The composition according to claim 1 , wherein the agent comprises oligogalacturonides having a degree of polymerization between about 1 and about 5.
3. The composition according to claim 1 , wherein the agent comprises oligogalacturonides obtained by enzymatic hydrolysis of a pectin, the hydrolysis being performed by an enzyme cocktail comprising pectinases having polygalacturonase, methyl esterase and polygalacturonase lyase activities.
4. The composition according to claim 1 , wherein the agent enhances availability of α6β4 receptors for laminin V and α2β1 receptors for collagen IV.
5. The composition according to claim 1 , wherein the agent is at least partially methylated or esterified.
6. The composition according to claim 1 , wherein the agent comprises about 0.01% to about 5% by weight of the composition.
7. The composition according to claim 1 , further comprising at least one plant extract as another active component.
8. The composition according to claim 7 , wherein the plant extract is selected from the group consisting of yam and beta carotene.
9. A method of preparing oligogalacturonides comprising:
hydrolysis of a pectin solution at a concentration of about 0.1 to about 10% at an acidic pH, by addition to the pectin solution of an enzyme solution of about 10 to about 1000 polygalacturonase units to obtain in a final solution of about 1 to about 10 pectinase units;
stopping the hydrolysis;
separating resulting high-molecular-weight polymers from the final solution; and
recovering the oligogalacturonides.
10. The method according to claim 9 , wherein the hydrolysis of the pectin solution is performed with an enzyme solution comprising pectinases comprising polygalacturonase, methyl esterase and polygalacturonase lyase activities.
11. The method according to claim 9 , wherein the hydrolysis is performed at a pH of about 4.5, at about 50° C. for about 2 hours then stepped by heating at about 70° C. for about 1 hour or at about 100° C. for about 5 minutes.
12. The method according to claim 11 , wherein, after cooling, high-molecular-weight polymers are precipitated by addition of HCl 1N, then eliminated by centrifugation or by filtration, and the pH of the supernatant is readjusted to a value between about 6 and about 8.
13. A method of preventing aging of skin comprising applying a therapeutically effective amount of the composition comprising an agent stimulating adherence of basal keratinocytes to laminin V and/or collagen IV that reduces communication disturbances between a subject's dermis and epidermis and reduces diminishment in interkeratinocyte cohesion within the epidermis to the skin.
14. The composition according to claim 13 , wherein the agent comprises oligogalacturonides having a degree of polymerization between about 1 and about 5.
15. The composition according to claim 13 , wherein the agent comprises oligogalacturonides obtained by enzymatic hydrolysis of a pectin, the hydrolysis being performed by an enzyme cocktail comprising pectinases having polygalacturonase, methyl esterase and polygalacturonase lyase activities.
16. The composition according to claim 13 , wherein the agent enhances availability of α6β4 receptors for laminin V and α2β1 receptors for collagen IV.
17. The composition according to claim 13 , wherein the agent is at least partially methylated or esterified.
18. The composition according to claim 13 , wherein the agent comprises about 0.01% to about 5% by weight of the composition.
19. The composition according to claim 13 , further comprising at least one plant extract as another active component.
20. The composition according to claim 19 , wherein the plant extract is selected from the group consisting of yam and beta carotene.
21. A method of reducing decreases in interkeratinocyte cohesion is skin comprising an agent stimulating adherence of basal keratinocytes to laminin V and/or collagen IV that reduces communication disturbances between a subject's dermis and epidermis and reduces diminishment in interkeratinocyte cohesion within the epidermis to the skin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/894,945 US20070293433A1 (en) | 2001-11-08 | 2007-08-22 | Methods of treating aging of skin with oligosaccharides in cosmetic or dermatological compositions that stimulate adhesion of keratinocytes to major proteins of the dermoepidermal junction and restore epidermal cohesion |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0114463A FR2831819B1 (en) | 2001-11-08 | 2001-11-08 | USE OF OLIGOSACCHARIDES IN COSMETIC OR DERMATOLOGICAL COMPOSITIONS TO STIMULATE THE ADHESION OF KERATINOCYTES ON THE MAJOR PROTEINS OF THE DERMO-EPIDERMAL JUNCTION |
FRFR01/14463 | 2001-11-08 | ||
PCT/FR2002/003844 WO2003039509A1 (en) | 2001-11-08 | 2002-11-08 | Use of oligosaccharides in cosmetic or dermatological compositions for stimulating adherence of keratinocytes on the dermoepidermal junction major proteins and restoring epidermal cohesion |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2002/003844 Continuation WO2003039509A1 (en) | 2001-11-08 | 2002-11-08 | Use of oligosaccharides in cosmetic or dermatological compositions for stimulating adherence of keratinocytes on the dermoepidermal junction major proteins and restoring epidermal cohesion |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/894,945 Division US20070293433A1 (en) | 2001-11-08 | 2007-08-22 | Methods of treating aging of skin with oligosaccharides in cosmetic or dermatological compositions that stimulate adhesion of keratinocytes to major proteins of the dermoepidermal junction and restore epidermal cohesion |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040224892A1 true US20040224892A1 (en) | 2004-11-11 |
Family
ID=8869192
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/839,420 Abandoned US20040224892A1 (en) | 2001-11-08 | 2004-05-05 | Oligosaccharides in cosmetic or dermatological compositions for stimulating adhesion of keratinocytes to major proteins of the dermoepidermal junction and restoration of epidermal cohesion |
US11/894,945 Abandoned US20070293433A1 (en) | 2001-11-08 | 2007-08-22 | Methods of treating aging of skin with oligosaccharides in cosmetic or dermatological compositions that stimulate adhesion of keratinocytes to major proteins of the dermoepidermal junction and restore epidermal cohesion |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/894,945 Abandoned US20070293433A1 (en) | 2001-11-08 | 2007-08-22 | Methods of treating aging of skin with oligosaccharides in cosmetic or dermatological compositions that stimulate adhesion of keratinocytes to major proteins of the dermoepidermal junction and restore epidermal cohesion |
Country Status (4)
Country | Link |
---|---|
US (2) | US20040224892A1 (en) |
DE (1) | DE10297369T5 (en) |
FR (1) | FR2831819B1 (en) |
WO (1) | WO2003039509A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090075934A1 (en) * | 2007-06-28 | 2009-03-19 | Isabelle Bonnet | Use of sulfated oligosaccharides as slimming cosmetic ingredients |
JP2013529091A (en) * | 2010-06-09 | 2013-07-18 | シャネル パフュームズ ビューテ | MicroRNA inhibitors for use in preventing and / or reducing skin aging and / or moisturizing skin |
US8604001B2 (en) | 2007-06-28 | 2013-12-10 | Basf Beauty Care Solutions France S.A.S. | Use of sulfated oligosaccharides as slimming cosmetic ingredients |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2852242B1 (en) * | 2003-03-13 | 2007-09-14 | USE OF OLIGOGALACTURONIDES IN COSMETICS OR FOR THE PREPARATION OF A DERMATOLOGICAL OR PHARMACEUTICAL COMPOSITION | |
FR2854573B1 (en) * | 2003-05-06 | 2006-08-04 | Rocher Yves Biolog Vegetale | USE OF OLIGOSACCHARIDES IN COSMETIC OR DERMATOLOGICAL COMPOSITIONS FOR STIMULATING THE DIFFERENTIATION OF EPIDERMIC CELLS |
MX2008013788A (en) * | 2008-10-16 | 2010-04-16 | Miguel Angel Martinez Tellez | Method for controlling the table grape colouring, from oligogalacturonides. |
FR3004936B1 (en) | 2013-04-24 | 2016-02-05 | Univ Reims Champagne Ardenne | PROCESS FOR OBTAINING A MIXTURE OF NEUTRAL OLIGOSACCHARIDES EXTRACTED FROM FLAXSEED |
FR3012334A1 (en) * | 2013-10-29 | 2015-05-01 | World Cosmetics | ANTI AGE COSMETIC COMPOSITION |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4105783A (en) * | 1975-07-23 | 1978-08-08 | Yu Ruey J | Therapeutic treatment of dry skin |
US5124313A (en) * | 1989-06-02 | 1992-06-23 | Schaeffer Hans A | Methods of improved skin care and the treatment of dermatological conditions |
US5561155A (en) * | 1986-12-23 | 1996-10-01 | Tristrata Technology, Inc. | Method of treating wrinkles using galacturonic acid or galacturonolactone |
US5683991A (en) * | 1993-09-10 | 1997-11-04 | Laevosan-Gesellschaft | Blocking the attachment of germs to human cells |
US5958474A (en) * | 1996-08-21 | 1999-09-28 | Nestec S.A. | Process for preparing food flavor precursors |
US6110478A (en) * | 1996-06-12 | 2000-08-29 | Laboratoire Oenobiol | Composition having tanning and photoprotective activity, and its cosmetic applications |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0948732A (en) * | 1995-08-04 | 1997-02-18 | Pola Chem Ind Inc | Activated oxygen scavenging agent and composition containing the same |
JP3668538B2 (en) * | 1995-08-30 | 2005-07-06 | ポーラ化成工業株式会社 | Active oxygen scavenger and composition containing the same |
DE10006989A1 (en) * | 2000-02-16 | 2001-08-23 | Nutricia Nv | Pharmaceutical or dietetic preparation for preventing cellular adhesion of pathogens, e.g. in treatment of infections, comprising carbohydrate having double bond-containing terminal uronic acid unit |
DE10019076A1 (en) * | 2000-04-06 | 2001-10-18 | Lang Christine | Use of polygalacturonides as food additives |
FR2854573B1 (en) * | 2003-05-06 | 2006-08-04 | Rocher Yves Biolog Vegetale | USE OF OLIGOSACCHARIDES IN COSMETIC OR DERMATOLOGICAL COMPOSITIONS FOR STIMULATING THE DIFFERENTIATION OF EPIDERMIC CELLS |
-
2001
- 2001-11-08 FR FR0114463A patent/FR2831819B1/en not_active Expired - Lifetime
-
2002
- 2002-11-08 DE DE10297369T patent/DE10297369T5/en not_active Withdrawn
- 2002-11-08 WO PCT/FR2002/003844 patent/WO2003039509A1/en not_active Application Discontinuation
-
2004
- 2004-05-05 US US10/839,420 patent/US20040224892A1/en not_active Abandoned
-
2007
- 2007-08-22 US US11/894,945 patent/US20070293433A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4105783A (en) * | 1975-07-23 | 1978-08-08 | Yu Ruey J | Therapeutic treatment of dry skin |
US5561155A (en) * | 1986-12-23 | 1996-10-01 | Tristrata Technology, Inc. | Method of treating wrinkles using galacturonic acid or galacturonolactone |
US5124313A (en) * | 1989-06-02 | 1992-06-23 | Schaeffer Hans A | Methods of improved skin care and the treatment of dermatological conditions |
US5683991A (en) * | 1993-09-10 | 1997-11-04 | Laevosan-Gesellschaft | Blocking the attachment of germs to human cells |
US6110478A (en) * | 1996-06-12 | 2000-08-29 | Laboratoire Oenobiol | Composition having tanning and photoprotective activity, and its cosmetic applications |
US5958474A (en) * | 1996-08-21 | 1999-09-28 | Nestec S.A. | Process for preparing food flavor precursors |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090075934A1 (en) * | 2007-06-28 | 2009-03-19 | Isabelle Bonnet | Use of sulfated oligosaccharides as slimming cosmetic ingredients |
US8153611B2 (en) | 2007-06-28 | 2012-04-10 | Basf Beauty Care Solutions France S.A.S. | Use of sulfated oligosaccharides as slimming cosmetic ingredients |
US8604001B2 (en) | 2007-06-28 | 2013-12-10 | Basf Beauty Care Solutions France S.A.S. | Use of sulfated oligosaccharides as slimming cosmetic ingredients |
JP2013529091A (en) * | 2010-06-09 | 2013-07-18 | シャネル パフュームズ ビューテ | MicroRNA inhibitors for use in preventing and / or reducing skin aging and / or moisturizing skin |
Also Published As
Publication number | Publication date |
---|---|
FR2831819B1 (en) | 2004-09-03 |
DE10297369T5 (en) | 2004-10-28 |
FR2831819A1 (en) | 2003-05-09 |
WO2003039509A1 (en) | 2003-05-15 |
US20070293433A1 (en) | 2007-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070293433A1 (en) | Methods of treating aging of skin with oligosaccharides in cosmetic or dermatological compositions that stimulate adhesion of keratinocytes to major proteins of the dermoepidermal junction and restore epidermal cohesion | |
KR102268324B1 (en) | A topical composition comprising small RNA lichen extract and cosmetic care method for reducing skin signs of aging | |
KR101323487B1 (en) | Antiwrinkle agent | |
CN109152724B (en) | Synergistic extract of palmaria palmiformis and jasmine, composition containing synergistic extract and application of synergistic extract | |
US6531132B1 (en) | Process for the extraction of an active principle from yeast for the treatment of wrinkles and cosmetic compositions thereof | |
EP0668072A1 (en) | Cosmetic composition containing a plant extracellular matrix extract | |
KR20210107724A (en) | rosewood extract | |
KR102139472B1 (en) | Anti-aging composition comprising functional peptides and fermented products | |
CN108703909B (en) | Composition with anti-wrinkle and anti-aging effects and application of composition in cosmetics | |
JPH09241146A (en) | Skin external agent | |
US6004568A (en) | Cosmetic or pharmaceutical, particularly dermatological, composition containing a Bertholletia extract | |
US8293287B2 (en) | Use of a Brassocattleya marcella Koss orchid extract as an active agent to prevent or delay the appearance of signs of cutaneous aging | |
US20070042064A1 (en) | Extracts of durian fruit for use in skin care compositions | |
KR20210144725A (en) | Anti-aging, antioxidant, anti-inflammatory and whitening agents, and cosmetics | |
KR101749657B1 (en) | Cosmetic Composition Comprising Fermented product of Dendropanax morbifera Sap as Active Ingredient | |
JPH06336422A (en) | External agent for skin | |
CN108785136B (en) | Application of cedar essential oil | |
CN108992360A (en) | It is a kind of add natural plant extracts skin care compositions and facial mask preparation method | |
US20070065386A1 (en) | Use of oligosaccharides in cosmetic, food or dermatological compositions for stimulating the differentiation of epidermal cell | |
FR3111543A1 (en) | NEW USES OF A ROSEWOOD EXTRACT | |
KR101957435B1 (en) | Method for preparing extract of fermented silkworm cocoon for improving antiwrinkle and a cosmetic composition containing the fermented extract of silkworm cocoon as an active ingredients | |
KR20150031365A (en) | Cosmetic Composition for Improving Skin Wrinkle Comprising the Fulvic acid | |
KR101825178B1 (en) | Cosmetic composition comprising extract of dendropanax morbifera and d-asparatic acid with reinforced wrinkle elimanatin and whitening effect | |
FR3018448A1 (en) | ACTIVE PRINCIPLE OBTAINED FROM ALGAE HYPNEA MUSCIFORMIS AND COSMETIC USES | |
KR20140072419A (en) | Anti-Wrinkle Composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: LABORATOIRES DE BIOLOGIE VEGETALE YVES ROCHER, FRA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LUBRANO, CHRISTIAN;FLAVET, LAURENCE;SAINTIGNY GAELLE;AND OTHERS;REEL/FRAME:015567/0880 Effective date: 20040608 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |